Biomedicine. Combating Parkinson's disease--step three
1Department of Neuroscience, Karolinska Institute, 171 77 Stockholm, Sweden. lars.olson@neuro.ki.se
Science (New York, N.Y.)
|February 24, 2001
Summary
Gene therapy using GDNF can protect dopamine neurons and improve motor function in Parkinson's disease models. This approach offers a potential new treatment strategy for this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Gene Therapy
- Neurodegenerative Diseases
Background:
- Parkinson's disease (PD) is characterized by the progressive loss of dopamine neurons in the nigrostriatal pathway.
- This neuronal degeneration leads to severe motor impairments, significantly impacting patient quality of life.
Discussion:
- A study investigated the use of a lentiviral vector to deliver the gene for glial cell line-derived neurotrophic factor (GDNF).
- GDNF is a crucial trophic factor known to support dopamine neuron survival and function.
Key Insights:
- Intra-nigrostriatal injection of the GDNF-encoding lentiviral vector in a primate model of PD prevented further loss of dopamine neurons.
- The treatment also resulted in a notable reversal of established motor deficits associated with the disease.
Outlook:
- This research highlights the therapeutic potential of gene therapy with GDNF for Parkinson's disease.
- Further development could lead to novel strategies for neuroprotection and functional recovery in PD patients.
More Related Videos
08:15Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:28Biological Methods for Microbial Control
Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
01:26Rocky Mountain Spotted Fever
Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...